Catalyst

Slingshot members are tracking this event:

Phase 2 pivotal first data of Brigatinib - ALTA trial for Anaplastic lymphoma kinase positive (ALK+) metastatic non-small cell lung cancer (NSCLC) due at ASCO 2016

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
ARIA Community voting in process
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jun 06, 2016
Occurred Source:
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Anaplastic Lymphoma Kinase Inhibitor, Alta Trial, Phase 2, Brigatinib, Nsclc, Alk In Lung Cancer Trial Of Ap26113